Scholar Rock Advances Apitegromab FDA Review for Spinal Muscular Atrophy

Key Points

• Scholar Rock said the FDA review of apitegromab for spinal muscular atrophy is progressing with the company’s second fill-finish manufacturing facility.
• The company expects a potential FDA decision by the September 30, 2026 PDUFA action date.
• Scholar Rock submitted the FDA-agreed data package for the second facility ahead of schedule and says it has sufficient supply to support a commercial launch if apitegromab is approved.

Scholar Rock (Nasdaq: SRRK) has provided an update on the FDA review of apitegromab, its investigational therapy for children and adults with spinal muscular atrophy, or SMA. The company said the biologics license application, or BLA, remains on track for a potential FDA decision by September 30, 2026, with the review progressing through its second fill-finish manufacturing facility.

FDA review now moves forward with Scholar Rock’s second manufacturing site

Scholar Rock said the FDA’s review will proceed solely with the company’s second fill-finish facility. This site is intended to provide the manufacturing path for apitegromab if the treatment receives regulatory approval.

During a March 2026 Type C meeting, Scholar Rock and the FDA agreed on the data required for the agency to assess the second facility. Scholar Rock has since submitted that information ahead of the agreed timeline, and the company said the review is progressing.

September 30 PDUFA date remains the key regulatory milestone

The FDA accepted Scholar Rock’s resubmitted BLA for apitegromab in May 2026 and assigned a September 30, 2026 PDUFA target action date. BLA acceptance means the FDA determined that the application was sufficiently complete to begin a formal review; it does not guarantee approval.

For SRRK investors, the September action date is the most important near-term catalyst. A positive decision could allow Scholar Rock to commercialize apitegromab in the United States for eligible people living with SMA, while a delay, complete response letter, or rejection would materially alter the company’s near-term outlook.

Manufacturing update follows prior FDA complete response letter

Apitegromab’s first BLA received a complete response letter from the FDA in September 2025 due to manufacturing observations at a Catalent fill-finish facility. Scholar Rock said at the time that the letter did not cite concerns with apitegromab’s clinical efficacy, safety profile, or its third-party drug-substance manufacturer.

The use of a separate fill-finish facility is therefore significant. It is intended to address the manufacturing-related regulatory pathway that affected the earlier filing, although FDA approval remains dependent on the agency’s full review of the BLA and manufacturing information.

Apitegromab targets motor-function needs in spinal muscular atrophy

Apitegromab is a selective myostatin inhibitor designed to support muscle growth and improve motor function in people with SMA. It is being developed as a potential treatment for children and adults, including patients who may be receiving existing disease-modifying SMA therapies.

SMA is a rare, genetic neuromuscular disease that causes progressive muscle weakness. The treatment opportunity is significant because meaningful unmet needs can remain for patients despite currently available therapies, particularly around improving strength and motor performance.

What the apitegromab update means for SRRK investors

The latest update reduces some uncertainty around apitegromab’s manufacturing pathway by confirming that FDA review is continuing with the second fill-finish site. Scholar Rock also says it has ample commercial supply available from that facility should apitegromab be approved.

Still, the FDA decision is not assured. Investors should monitor any changes to the September 30 PDUFA date, FDA communications related to manufacturing, launch readiness, commercial-access plans, and the company’s cash position as Scholar Rock approaches the regulatory decision.